Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 562

1.

Quantification of biological age as a determinant of age-related diseases in the Rotterdam Study: a structural equation modeling approach.

Waziry R, Gras L, Sedaghat S, Tiemeier H, Weverling GJ, Ghanbari M, Klap J, de Wolf F, Hofman A, Ikram MA, Goudsmit J.

Eur J Epidemiol. 2019 Aug;34(8):793-799. doi: 10.1007/s10654-019-00497-3. Epub 2019 Apr 13.

PMID:
30993509
2.

A small-molecule fusion inhibitor of influenza virus is orally active in mice.

van Dongen MJP, Kadam RU, Juraszek J, Lawson E, Brandenburg B, Schmitz F, Schepens WBG, Stoops B, van Diepen HA, Jongeneelen M, Tang C, Vermond J, van Eijgen-Obregoso Real A, Blokland S, Garg D, Yu W, Goutier W, Lanckacker E, Klap JM, Peeters DCG, Wu J, Buyck C, Jonckers THM, Roymans D, Roevens P, Vogels R, Koudstaal W, Friesen RHE, Raboisson P, Dhanak D, Goudsmit J, Wilson IA.

Science. 2019 Mar 8;363(6431). pii: eaar6221. doi: 10.1126/science.aar6221.

PMID:
30846569
3.

Naturally occurring antibodies isolated from PD patients inhibit synuclein seeding in vitro and recognize Lewy pathology.

Li X, Koudstaal W, Fletcher L, Costa M, van Winsen M, Siregar B, Inganäs H, Kim J, Keogh E, Macedo J, Holland T, Perry S, Bard F, Hoozemans JJ, Goudsmit J, Apetri A, Pascual G.

Acta Neuropathol. 2019 May;137(5):825-836. doi: 10.1007/s00401-019-01974-5. Epub 2019 Feb 25.

4.

Structural Basis for Recognition of a Unique Epitope by a Human Anti-tau Antibody.

Zhang H, Zhu X, Pascual G, Wadia JS, Keogh E, Hoozemans JJ, Siregar B, Inganäs H, Stoop EJM, Goudsmit J, Apetri A, Koudstaal W, Wilson IA.

Structure. 2018 Dec 4;26(12):1626-1634.e4. doi: 10.1016/j.str.2018.08.012. Epub 2018 Oct 11.

PMID:
30318466
5.

A common antigenic motif recognized by naturally occurring human VH5-51/VL4-1 anti-tau antibodies with distinct functionalities.

Apetri A, Crespo R, Juraszek J, Pascual G, Janson R, Zhu X, Zhang H, Keogh E, Holland T, Wadia J, Verveen H, Siregar B, Mrosek M, Taggenbrock R, Ameijde J, Inganäs H, van Winsen M, Koldijk MH, Zuijdgeest D, Borgers M, Dockx K, Stoop EJM, Yu W, Brinkman-van der Linden EC, Ummenthum K, van Kolen K, Mercken M, Steinbacher S, de Marco D, Hoozemans JJ, Wilson IA, Koudstaal W, Goudsmit J.

Acta Neuropathol Commun. 2018 May 31;6(1):43. doi: 10.1186/s40478-018-0543-z.

6.

Temporal association patterns and dynamics of amyloid-β and tau in Alzheimer's disease.

Ower AK, Hadjichrysanthou C, Gras L, Goudsmit J, Anderson RM, de Wolf F; Alzheimer’s Disease Neuroimaging Initiative.

Eur J Epidemiol. 2018 Jul;33(7):657-666. doi: 10.1007/s10654-017-0326-z. Epub 2017 Oct 25.

7.

In Vitro Neutralization Is Not Predictive of Prophylactic Efficacy of Broadly Neutralizing Monoclonal Antibodies CR6261 and CR9114 against Lethal H2 Influenza Virus Challenge in Mice.

Sutton TC, Lamirande EW, Bock KW, Moore IN, Koudstaal W, Rehman M, Weverling GJ, Goudsmit J, Subbarao K.

J Virol. 2017 Nov 30;91(24). pii: e01603-17. doi: 10.1128/JVI.01603-17. Print 2017 Dec 15.

8.

Potent peptidic fusion inhibitors of influenza virus.

Kadam RU, Juraszek J, Brandenburg B, Buyck C, Schepens WBG, Kesteleyn B, Stoops B, Vreeken RJ, Vermond J, Goutier W, Tang C, Vogels R, Friesen RHE, Goudsmit J, van Dongen MJP, Wilson IA.

Science. 2017 Oct 27;358(6362):496-502. doi: 10.1126/science.aan0516. Epub 2017 Sep 28.

9.

Maternal antibodies protect offspring from severe influenza infection and do not lead to detectable interference with subsequent offspring immunization.

van der Lubbe JEM, Vreugdenhil J, Damman S, Vaneman J, Klap J, Goudsmit J, Radošević K, Roozendaal R.

Virol J. 2017 Jun 26;14(1):123. doi: 10.1186/s12985-017-0787-4.

10.

Immunological memory to hyperphosphorylated tau in asymptomatic individuals.

Pascual G, Wadia JS, Zhu X, Keogh E, Kükrer B, van Ameijde J, Inganäs H, Siregar B, Perdok G, Diefenbach O, Nahar T, Sprengers I, Koldijk MH, der Linden EC, Peferoen LA, Zhang H, Yu W, Li X, Wagner M, Moreno V, Kim J, Costa M, West K, Fulton Z, Chammas L, Luckashenak N, Fletcher L, Holland T, Arnold C, Anthony Williamson R, Hoozemans JJ, Apetri A, Bard F, Wilson IA, Koudstaal W, Goudsmit J.

Acta Neuropathol. 2017 May;133(5):767-783. doi: 10.1007/s00401-017-1705-y. Epub 2017 Mar 24.

11.

HA Antibody-Mediated FcγRIIIa Activity Is Both Dependent on FcR Engagement and Interactions between HA and Sialic Acids.

Cox F, Kwaks T, Brandenburg B, Koldijk MH, Klaren V, Smal B, Korse HJ, Geelen E, Tettero L, Zuijdgeest D, Stoop EJ, Saeland E, Vogels R, Friesen RH, Koudstaal W, Goudsmit J.

Front Immunol. 2016 Sep 29;7:399. eCollection 2016.

12.

The incubation period of Alzheimer's disease and the timing of tau versus amyloid misfolding and spreading within the brain.

Goudsmit J.

Eur J Epidemiol. 2016 Feb;31(2):99-105. doi: 10.1007/s10654-016-0144-8. Epub 2016 Mar 26. No abstract available.

13.

Protection against H5N1 Influenza Virus Induced by Matrix-M Adjuvanted Seasonal Virosomal Vaccine in Mice Requires Both Antibodies and T Cells.

Cox F, Baart M, Huizingh J, Tolboom J, Dekking L, Goudsmit J, Saeland E, Radošević K.

PLoS One. 2015 Dec 22;10(12):e0145243. doi: 10.1371/journal.pone.0145243. eCollection 2015.

14.

Matrix-M™ adjuvation broadens protection induced by seasonal trivalent virosomal influenza vaccine.

Cox F, Saeland E, Baart M, Koldijk M, Tolboom J, Dekking L, Koudstaal W, Lövgren Bengtsson K, Goudsmit J, Radošević K.

Virol J. 2015 Dec 8;12:210. doi: 10.1186/s12985-015-0435-9.

15.

Matrix-M Adjuvated Seasonal Virosomal Influenza Vaccine Induces Partial Protection in Mice and Ferrets against Avian H5 and H7 Challenge.

Cox F, Roos A, Hafkemeijer N, Baart M, Tolboom J, Dekking L, Stittelaar K, Goudsmit J, Radošević K, Saeland E.

PLoS One. 2015 Sep 24;10(9):e0135723. doi: 10.1371/journal.pone.0135723. eCollection 2015.

16.

A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen.

Impagliazzo A, Milder F, Kuipers H, Wagner MV, Zhu X, Hoffman RM, van Meersbergen R, Huizingh J, Wanningen P, Verspuij J, de Man M, Ding Z, Apetri A, Kükrer B, Sneekes-Vriese E, Tomkiewicz D, Laursen NS, Lee PS, Zakrzewska A, Dekking L, Tolboom J, Tettero L, van Meerten S, Yu W, Koudstaal W, Goudsmit J, Ward AB, Meijberg W, Wilson IA, Radošević K.

Science. 2015 Sep 18;349(6254):1301-6. doi: 10.1126/science.aac7263. Epub 2015 Aug 24.

17.

Protection against H5N1 by multiple immunizations with seasonal influenza vaccine in mice is correlated with H5 cross-reactive antibodies.

Roos A, Roozendaal R, Theeuwsen J, Riahi S, Vaneman J, Tolboom J, Dekking L, Koudstaal W, Goudsmit J, Radošević K.

Vaccine. 2015 Mar 30;33(14):1739-47. doi: 10.1016/j.vaccine.2015.01.070. Epub 2015 Feb 7.

PMID:
25659276
18.

Relating influenza virus membrane fusion kinetics to stoichiometry of neutralizing antibodies at the single-particle level.

Otterstrom JJ, Brandenburg B, Koldijk MH, Juraszek J, Tang C, Mashaghi S, Kwaks T, Goudsmit J, Vogels R, Friesen RH, van Oijen AM.

Proc Natl Acad Sci U S A. 2014 Dec 2;111(48):E5143-8. doi: 10.1073/pnas.1411755111. Epub 2014 Nov 17.

19.

Retrospective. Joep Lange (1954-2014).

Goudsmit J.

Science. 2014 Aug 22;345(6199):881. doi: 10.1126/science.1259453. No abstract available.

PMID:
25146275
20.

Transient humoral protection against H5N1 challenge after seasonal influenza vaccination of humans.

Roozendaal R, Tolboom J, Roos A, Riahi S, Theeuwsen J, Bujny MV, Klaren V, Korse HJ, Dekking L, Grootenhuis A, Weverling GJ, Koudstaal W, Goudsmit J, Radošević K.

PLoS One. 2014 Jul 30;9(7):e103550. doi: 10.1371/journal.pone.0103550. eCollection 2014.

21.

Mechanisms of hemagglutinin targeted influenza virus neutralization.

Brandenburg B, Koudstaal W, Goudsmit J, Klaren V, Tang C, Bujny MV, Korse HJ, Kwaks T, Otterstrom JJ, Juraszek J, van Oijen AM, Vogels R, Friesen RH.

PLoS One. 2013 Dec 11;8(12):e80034. doi: 10.1371/journal.pone.0080034. eCollection 2013.

22.

A common solution to group 2 influenza virus neutralization.

Friesen RH, Lee PS, Stoop EJ, Hoffman RM, Ekiert DC, Bhabha G, Yu W, Juraszek J, Koudstaal W, Jongeneelen M, Korse HJ, Ophorst C, Brinkman-van der Linden EC, Throsby M, Kwakkenbos MJ, Bakker AQ, Beaumont T, Spits H, Kwaks T, Vogels R, Ward AB, Goudsmit J, Wilson IA.

Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):445-50. doi: 10.1073/pnas.1319058110. Epub 2013 Dec 11.

23.

Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species.

Zahn R, Gillisen G, Roos A, Koning M, van der Helm E, Spek D, Weijtens M, Grazia Pau M, Radošević K, Weverling GJ, Custers J, Vellinga J, Schuitemaker H, Goudsmit J, Rodríguez A.

PLoS One. 2012;7(12):e44115. doi: 10.1371/journal.pone.0044115. Epub 2012 Dec 6.

24.

First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001).

Baden LR, Walsh SR, Seaman MS, Tucker RP, Krause KH, Patel A, Johnson JA, Kleinjan J, Yanosick KE, Perry J, Zablowsky E, Abbink P, Peter L, Iampietro MJ, Cheung A, Pau MG, Weijtens M, Goudsmit J, Swann E, Wolff M, Loblein H, Dolin R, Barouch DH.

J Infect Dis. 2013 Jan 15;207(2):240-7. doi: 10.1093/infdis/jis670. Epub 2012 Nov 2.

25.

Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001).

Barouch DH, Liu J, Peter L, Abbink P, Iampietro MJ, Cheung A, Alter G, Chung A, Dugast AS, Frahm N, McElrath MJ, Wenschuh H, Reimer U, Seaman MS, Pau MG, Weijtens M, Goudsmit J, Walsh SR, Dolin R, Baden LR.

J Infect Dis. 2013 Jan 15;207(2):248-56. doi: 10.1093/infdis/jis671. Epub 2012 Nov 2.

26.

PER.C6(®) cells as a serum-free suspension cell platform for the production of high titer poliovirus: a potential low cost of goods option for world supply of inactivated poliovirus vaccine.

Sanders BP, Edo-Matas D, Custers JH, Koldijk MH, Klaren V, Turk M, Luitjens A, Bakker WA, Uytdehaag F, Goudsmit J, Lewis JA, Schuitemaker H.

Vaccine. 2013 Jan 21;31(5):850-6. doi: 10.1016/j.vaccine.2012.10.070. Epub 2012 Oct 30.

PMID:
23123018
27.

Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous delivery.

Coughlan L, Bradshaw AC, Parker AL, Robinson H, White K, Custers J, Goudsmit J, Van Roijen N, Barouch DH, Nicklin SA, Baker AH.

Mol Ther. 2012 Dec;20(12):2268-81. doi: 10.1038/mt.2012.162. Epub 2012 Aug 28.

28.

Highly conserved protective epitopes on influenza B viruses.

Dreyfus C, Laursen NS, Kwaks T, Zuijdgeest D, Khayat R, Ekiert DC, Lee JH, Metlagel Z, Bujny MV, Jongeneelen M, van der Vlugt R, Lamrani M, Korse HJ, Geelen E, Sahin Ö, Sieuwerts M, Brakenhoff JP, Vogels R, Li OT, Poon LL, Peiris M, Koudstaal W, Ward AB, Wilson IA, Goudsmit J, Friesen RH.

Science. 2012 Sep 14;337(6100):1343-8. doi: 10.1126/science.1222908. Epub 2012 Aug 9.

29.

Priming T-cell responses with recombinant measles vaccine vector in a heterologous prime-boost setting in non-human primates.

Bolton DL, Santra S, Swett-Tapia C, Custers J, Song K, Balachandran H, Mach L, Naim H, Kozlowski PA, Lifton M, Goudsmit J, Letvin N, Roederer M, Radošević K.

Vaccine. 2012 Sep 7;30(41):5991-8. doi: 10.1016/j.vaccine.2012.06.029. Epub 2012 Jun 22.

30.

T-helper 1 cells elicited by H5N1 vaccination predict seroprotection.

Pedersen GK, Madhun AS, Breakwell L, Hoschler K, Sjursen H, Pathirana RD, Goudsmit J, Cox RJ.

J Infect Dis. 2012 Jul 15;206(2):158-66. doi: 10.1093/infdis/jis330. Epub 2012 May 2.

PMID:
22551811
31.

Validation of the rapid fluorescent focus inhibition test for rabies virus-neutralizing antibodies in clinical samples.

Kostense S, Moore S, Companjen A, Bakker AB, Marissen WE, von Eyben R, Weverling GJ, Hanlon C, Goudsmit J.

Antimicrob Agents Chemother. 2012 Jul;56(7):3524-30. doi: 10.1128/AAC.06179-11. Epub 2012 Apr 30.

32.

A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity.

Hoft DF, Blazevic A, Stanley J, Landry B, Sizemore D, Kpamegan E, Gearhart J, Scott A, Kik S, Pau MG, Goudsmit J, McClain JB, Sadoff J.

Vaccine. 2012 Mar 9;30(12):2098-108. doi: 10.1016/j.vaccine.2012.01.048. Epub 2012 Jan 30.

PMID:
22296955
33.

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys.

Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, Iampietro MJ, SanMiguel A, Seaman MS, Ferrari G, Forthal DN, Ourmanov I, Hirsch VM, Carville A, Mansfield KG, Stablein D, Pau MG, Schuitemaker H, Sadoff JC, Billings EA, Rao M, Robb ML, Kim JH, Marovich MA, Goudsmit J, Michael NL.

Nature. 2012 Jan 4;482(7383):89-93. doi: 10.1038/nature10766.

34.

A recombinant Bacille Calmette-Guérin construct expressing the Plasmodium falciparum circumsporozoite protein enhances dendritic cell activation and primes for circumsporozoite-specific memory cells in BALB/c mice.

Arama C, Waseem S, Fernández C, Assefaw-Redda Y, You L, Rodriguez A, Radošević K, Goudsmit J, Kaufmann SH, Reece ST, Troye-Blomberg M.

Vaccine. 2012 Aug 10;30(37):5578-84. doi: 10.1016/j.vaccine.2011.09.054. Epub 2011 Oct 6.

PMID:
21983157
35.

A highly conserved neutralizing epitope on group 2 influenza A viruses.

Ekiert DC, Friesen RH, Bhabha G, Kwaks T, Jongeneelen M, Yu W, Ophorst C, Cox F, Korse HJ, Brandenburg B, Vogels R, Brakenhoff JP, Kompier R, Koldijk MH, Cornelissen LA, Poon LL, Peiris M, Koudstaal W, Wilson IA, Goudsmit J.

Science. 2011 Aug 12;333(6044):843-50. doi: 10.1126/science.1204839. Epub 2011 Jul 7.

36.

International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations.

Barouch DH, Kik SV, Weverling GJ, Dilan R, King SL, Maxfield LF, Clark S, Ng'ang'a D, Brandariz KL, Abbink P, Sinangil F, de Bruyn G, Gray GE, Roux S, Bekker LG, Dilraj A, Kibuuka H, Robb ML, Michael NL, Anzala O, Amornkul PN, Gilmour J, Hural J, Buchbinder SP, Seaman MS, Dolin R, Baden LR, Carville A, Mansfield KG, Pau MG, Goudsmit J.

Vaccine. 2011 Jul 18;29(32):5203-9. doi: 10.1016/j.vaccine.2011.05.025. Epub 2011 May 25.

37.

A peptide-based Plasmodium falciparum circumsporozoite assay to test for serum antibody responses to pre-erythrocyte malaria vaccines.

Kostense S, Mommaas B, Hendriks J, Verhoeven M, Ter Haak M, Tirion F, Wiesken E, Pau MG, Radosevic K, Goudsmit J.

Clin Vaccine Immunol. 2011 May;18(5):776-82. doi: 10.1128/CVI.00547-10. Epub 2011 Mar 16.

38.

Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge.

Geisbert TW, Bailey M, Hensley L, Asiedu C, Geisbert J, Stanley D, Honko A, Johnson J, Mulangu S, Pau MG, Custers J, Vellinga J, Hendriks J, Jahrling P, Roederer M, Goudsmit J, Koup R, Sullivan NJ.

J Virol. 2011 May;85(9):4222-33. doi: 10.1128/JVI.02407-10. Epub 2011 Feb 16.

39.

Genetic immunization in the lung induces potent local and systemic immune responses.

Song K, Bolton DL, Wei CJ, Wilson RL, Camp JV, Bao S, Mattapallil JJ, Herzenberg LA, Herzenberg LA, Andrews CA, Sadoff JC, Goudsmit J, Pau MG, Seder RA, Kozlowski PA, Nabel GJ, Roederer M, Rao SS.

Proc Natl Acad Sci U S A. 2010 Dec 21;107(51):22213-8. doi: 10.1073/pnas.1015536108. Epub 2010 Dec 6. Erratum in: Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2629. Wei, Chih-Jen [added].

40.

A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults.

Ledgerwood JE, Costner P, Desai N, Holman L, Enama ME, Yamshchikov G, Mulangu S, Hu Z, Andrews CA, Sheets RA, Koup RA, Roederer M, Bailer R, Mascola JR, Pau MG, Sullivan NJ, Goudsmit J, Nabel GJ, Graham BS; VRC 205 Study Team.

Vaccine. 2010 Dec 16;29(2):304-13. doi: 10.1016/j.vaccine.2010.10.037. Epub 2010 Oct 27.

PMID:
21034824
41.

Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354.

Kaufmann B, Vogt MR, Goudsmit J, Holdaway HA, Aksyuk AA, Chipman PR, Kuhn RJ, Diamond MS, Rossmann MG.

Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18950-5. doi: 10.1073/pnas.1011036107. Epub 2010 Oct 18.

42.

The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert.

Radosevic K, Rodriguez A, Lemckert AA, van der Meer M, Gillissen G, Warnar C, von Eyben R, Pau MG, Goudsmit J.

Clin Vaccine Immunol. 2010 Nov;17(11):1687-94. doi: 10.1128/CVI.00311-10. Epub 2010 Sep 8. Erratum in: Clin Vaccine Immunol. 2011 Feb;18(2):353.

43.

Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates.

Geisbert TW, Bailey M, Geisbert JB, Asiedu C, Roederer M, Grazia-Pau M, Custers J, Jahrling P, Goudsmit J, Koup R, Sullivan NJ.

J Virol. 2010 Oct;84(19):10386-94. doi: 10.1128/JVI.00594-10. Epub 2010 Jul 21.

44.

Differences in HIV type 1 RNA plasma load profile of closely related cocirculating Ethiopian subtype C strains: C and C'.

Ayele W, Mekonnen Y, Messele T, Mengistu Y, Tsegaye A, Bakker M, Berkhout B, Dorigo-Zetsma W, Wolday D, Goudsmit J, Coutinho R, de Baar M, Paxton WA, Pollakis G.

AIDS Res Hum Retroviruses. 2010 Jul;26(7):805-13. doi: 10.1089/aid.2009.0152.

PMID:
20624072
45.

Stabilizing formulations for inhalable powders of an adenovirus 35-vectored tuberculosis (TB) vaccine (AERAS-402).

Jin TH, Tsao E, Goudsmit J, Dheenadhayalan V, Sadoff J.

Vaccine. 2010 Jun 17;28(27):4369-75. doi: 10.1016/j.vaccine.2010.04.059. Epub 2010 May 2.

PMID:
20444437
46.

Rapid generation of a well-matched vaccine seed from a modern influenza A virus primary isolate without recourse to eggs.

Hartgroves LC, Koudstaal W, McLeod C, Moncorgé O, Thompson CI, Ellis J, Bull C, Havenga MJ, Goudsmit J, Barclay WS.

Vaccine. 2010 Apr 9;28(17):2973-9. doi: 10.1016/j.vaccine.2010.02.012. Epub 2010 Feb 25.

PMID:
20188682
47.

The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults.

Abel B, Tameris M, Mansoor N, Gelderbloem S, Hughes J, Abrahams D, Makhethe L, Erasmus M, de Kock M, van der Merwe L, Hawkridge A, Veldsman A, Hatherill M, Schirru G, Pau MG, Hendriks J, Weverling GJ, Goudsmit J, Sizemore D, McClain JB, Goetz M, Gearhart J, Mahomed H, Hussey GD, Sadoff JC, Hanekom WA.

Am J Respir Crit Care Med. 2010 Jun 15;181(12):1407-17. doi: 10.1164/rccm.200910-1484OC. Epub 2010 Feb 18.

48.

New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets.

Friesen RH, Koudstaal W, Koldijk MH, Weverling GJ, Brakenhoff JP, Lenting PJ, Stittelaar KJ, Osterhaus AD, Kompier R, Goudsmit J.

PLoS One. 2010 Feb 8;5(2):e9106. doi: 10.1371/journal.pone.0009106.

49.

Pre- and postexposure use of human monoclonal antibody against H5N1 and H1N1 influenza virus in mice: viable alternative to oseltamivir.

Koudstaal W, Koldijk MH, Brakenhoff JP, Cornelissen LA, Weverling GJ, Friesen RH, Goudsmit J.

J Infect Dis. 2009 Dec 15;200(12):1870-3. doi: 10.1086/648378.

PMID:
19911992
50.

Lack of in vivo compartmentalization among HIV-1 infected naïve and memory CD4+ T cell subsets.

Heeregrave EJ, Geels MJ, Brenchley JM, Baan E, Ambrozak DR, van der Sluis RM, Bennemeer R, Douek DC, Goudsmit J, Pollakis G, Koup RA, Paxton WA.

Virology. 2009 Oct 10;393(1):24-32. doi: 10.1016/j.virol.2009.07.011. Epub 2009 Aug 20.

Supplemental Content

Loading ...
Support Center